Author(s)

Amal Rayan^1*, Ahmed Soliman², Khalid F. Riad³, Asmaa M. Zahran⁴, Hosam A. Hasan⁵

¹Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
²General Surgery Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
³Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
⁴Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
⁵Radiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.

Background and aim of work: We aimed from this study to determine the response and local relapse free survival (RFS) of pediatric patients with localized Ewing’s sarcoma treated with accelerated hyper-fractionated RT. Patient and methods: This study was a nonrandomized uncontrolled phase II study and was conducted at clinical oncology department and south Egypt cancer institute; it involved 28 patients with histologically confirmed Ewing’s sarcoma; all of them were subjected to PET/CT whenever possible or MRI with contrast of the primary site, MSCT chest, bone scan, and LDH to ensure absence of metastasis followed by the protocol of accelerated hyper fractionated RT. Results: The overall response rate (ORR) was 92.9% by MRI with significant effect of the type of response on local RFS (P < 0.002). The median local RFS of 28 patients with localized Ewing’s sarcoma was 30 ± 8.599 months with 95% CI = 13.147 - 46.853; the 3-year local control was 35%. Conclusion: Accelerated hyper fractionated RT didn’t achieve better results than standard fractionation RT, but it is recommended to be done on a large sample size, and multiple centers, and continued follow up is also recommended to evaluate 5-year LRFS, 5-year OS.

Accelerated Hyper Fractionated RT, Ewing’s Sarcoma, Relapse Free Survival

Rayan, A. , Soliman, A. , Riad, K. , Zahran, A. and Hasan, H. (2018) Accelerated Hyper Fractionated Radiotherapy in Localized Ewing’s Sarcoma with or without Surgery: What’s New? A Phase II Study. Journal of Cancer Therapy, 9, 820-826. doi: 10.4236/jct.2018.910067.